108,000 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Acquired by State of Michigan Retirement System

State of Michigan Retirement System bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 108,000 shares of the company's stock, valued at approximately $6,734,000. State of Michigan Retirement System owned 0.32% of TransMedics Group at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. New York State Teachers Retirement System purchased a new position in TransMedics Group during the third quarter worth about $1,217,000. Farther Finance Advisors LLC boosted its position in shares of TransMedics Group by 187.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company's stock worth $76,000 after purchasing an additional 316 shares during the period. Amalgamated Bank increased its holdings in TransMedics Group by 777.4% in the 3rd quarter. Amalgamated Bank now owns 9,774 shares of the company's stock valued at $1,535,000 after purchasing an additional 8,660 shares during the last quarter. Principal Financial Group Inc. raised its position in TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company's stock valued at $31,759,000 after purchasing an additional 146,115 shares during the period. Finally, Cahill Wealth Management LLC lifted its stake in TransMedics Group by 28.4% during the third quarter. Cahill Wealth Management LLC now owns 3,486 shares of the company's stock worth $547,000 after purchasing an additional 771 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research note on Wednesday, February 5th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Canaccord Genuity Group dropped their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a "buy" rating for the company in a report on Wednesday, November 20th. Piper Sandler reduced their target price on shares of TransMedics Group from $110.00 to $90.00 and set an "overweight" rating on the stock in a report on Wednesday, December 11th. Finally, TD Cowen decreased their price target on shares of TransMedics Group from $175.00 to $120.00 and set a "buy" rating for the company in a research report on Monday, November 18th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, TransMedics Group has an average rating of "Moderate Buy" and a consensus target price of $122.70.

TransMedics Group Stock Down 2.1 %

Shares of TransMedics Group stock traded down $1.43 during trading hours on Monday, hitting $66.03. The company had a trading volume of 949,556 shares, compared to its average volume of 2,038,103. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company's 50-day moving average is $68.30 and its two-hundred day moving average is $97.19. The company has a market cap of $2.22 billion, a P/E ratio of 70.25 and a beta of 2.12. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.